| INTRODUC TI ON
The incidence of Clostridium difficile infection (CDI) has increased over the past 2 decades, 1,2 afflicting >1% of hospitalized patients. 3, 4 In patients with a history of solid organ transplantation (SOT), the impact is even more pronounced due to exposure to multiple CDI risk factors including hospitalization, profound immunosuppression, and frequent antibiotic exposure. [5] [6] [7] [8] CDI is the most frequent cause of infectious diarrhea in SOT patients, accounting for 11.8% of hospital-onset diarrhea cases. 9 Reported rates are 3%-19% in liver, 5,6,10,11 3.5%-16% in kidney, [10] [11] [12] 1.5%-7.8% in kidney-pancreas, 5, 12, 13 9% in small bowel, 10, 11 8%-15% in heart, 5,14 and 7%-31% in lung transplant recipients, 5, 15 with median onset of CDI at 31.5 days after transplantation. 16 SOT recipients also appear to be at higher risk for recurrent CDI (RCDI), with studies in heart and lung transplant recipients showing 28.6%-33.0% had 1 or more recurrences. 17 Progression to severe and fulminant CDI afflicts 13.8%-15.8% of SOT patients 7, 18 vs 8% of the general population.
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There is also a higher rate of CDI-related complications in these patients, including 23.1% colectomy, 53.8% mortality, and 30.8% graft loss. documented in immunocompromised patients. 20 Fidaxomicin may be preferred in SOT patients where data demonstrate decreases in recurrent CDI and avoidance of VRE colonization, but its use may be prohibitive in many clinical settings due to cost and availability.
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Among patients who fail medical management, CDI-related mortality approaches 70%-80%, 22, 23 and it only improves marginally following colectomy at approximately 50%. 22, 24 Immunosuppressive therapy may impair wound healing; thus SOT patients may face additional surgical complications when undergoing colectomy. 25, 26 Moreover, surgery often is not even an option for critically ill patients.
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The American College of Gastroenterology (ACG) and the IDSA both suggest that fecal microbiota transplantation (FMT) for RCDI should be considered following 3 or more episodes of CDI. 28, 29 FMT is superior to traditional anti-CDI therapy at inducing lasting cure.
The rate of recurrence in these patients is between 35% and 65% following a 10-day vancomycin course, 30 25% after a 10-day treatment with fidaxomicin, 31 while only 5%-15% recur after FMT. 32, 33 Recent evidence demonstrated that FMT is efficacious in severe and fulminant CDI both for cure 34 and improvement of patient outcomes such as mortality and colectomy rates. 35 Despite the proven efficacy of FMT in treating CDI, 36- .005
CMV, cytomegalovirus; FMT, fecal microbiota transplant; IBD, inflammatory bowel disease; SD, standard deviation.
| MATERIAL S AND ME THODS

| Study cohort and definitions
This multicenter, retrospective study included adult patients (age This study was approved by the Indiana University Institutional Review Board (IRB). The study protocol and data collection form were made available to all participating institutions for institutionspecific IRB approval.
| Statistical analysis
Baseline patient, SOT, CDI, and FMT characteristics were summarized using proportions for categorical variables, median, and interquartile ranges for skewed continuous variables, and mean and standard deviations for normally distributed continuous variables.
Differences between patients who had FMT success vs FMT failure at 1 and 3 months post-FMT were determined using Fisher exact test for categorical variables and nonparametric Wilcoxon rank sum for continuous variables.
Risk factors associated with FMT failure to achieve primary cure were identified using multivariable logistic regression. 
| RE SULTS
| Patient baseline characteristics
A total of 94 patients were included in the analysis for FMT failure at 1 month, and 92 patients at 3 months after 2 patients were excluded due to loss of follow-up. Patient demographics, clinical variables, and transplant characteristics were not significantly different between patients who had FMT success vs failure outcome at 1 and 3 months.
The only exception was mean number of immunosuppressive medications at time of FMT, which was on average higher in the FMT failure group vs FMT success group at both 1 and 3 months ( Table 1) .
Rate of retransplantation of SOT prior to FMT was marginally higher but not statistically significant in the FMT failure group compared to FMT success at 1 month (11.7% FMT success vs 26.5% FMT failure, P = .09). .62
| Characteristics of CDI and FMT
Presence of CDI-related hospitalization prior to FMT .07
Number of CDI-related hospitalization prior to FMT, median (IQR)
.041
.027
Number of CDI episodes prior to FMT, median (IQR)
(2-5)
.74
.47
Severe and fulminant CDI ( Table 2 
| FMT safety
Adverse events possibly related to FMT occurred in 22.3% (21/94) of patients and most frequently consisted of nausea, abdominal pain, abdominal cramping, and/or loose stools (Table 3) . In most cases, these events were rated as mild and occurred within the FMT-related diarrhea ± abdominal pain/cramping 9
Abdominal pain/cramping and nausea 6
Miscellaneous (dehydration, fever, rectal prolapse 
| FMT cure rates
The primary cure rate following a single FMT was 63.8% (60/94) at 
| Predictors of FMT failure
| D ISCUSS I ON
This multicenter, retrospective, observational study describes safety outcomes, effectiveness, and predictors of failure associated with FMT for the treatment of CDI in SOT recipients. The rate of AEs was low, generally described as self-limiting conditions such as abdominal pain or diarrhea. There were no cases of infectious AEs F I G U R E 2 Primary and overall cure rates for recurrent, severe, and fulminant CDI. CDI, Clostridium difficile infection attributed to FMT. Our data support a 63.8% cure rate at 1 month after first FMT and overall cure rate of 91.3% when including additional FMT(s) and CDI antibiotic treatments. We found that risk factors for FMT failure were similar to those in studies of non-SOT patients, including inpatient FMT administration, use of non-CDI antibiotics at the time of FMT, severe and fulminant disease, and presence of pseudomembranes.
We found that FMT is a safe option in the SOT population. Both nonserious AEs and SAEs occurred at comparable rates reported in the immunocompetent population. 46 Importantly, no infectious complications including bacteremia related to the fecal transplant material were reported. Post-FMT diarrhea was noted in 13.8% ( 63 has yielded superior cure rates and decreased association with mortality and colectomy in hospitalized patients. 35 In this protocol, presence of pseudomembranes during colonoscopic FMT delivery guides the need for additional therapy after FMT such as reinitiation of vancomycin followed by repeat FMT.
SOT patients may need to be evaluated by alternative criteria because immunosuppressive therapies limit pseudomembrane formation due to suppression of neutrophil cell counts, 69 and decreased capacity for neutrophil extracellular trap formation. 43 Thus, reliance on the presence of pseudomembranes to guide the need for further therapy may be less reliable in SOT patients. Optimal timing between repeated FMT treatments for SOT patients will need to be further evaluated.
There are several limitations of this study. While all patients included in our study previously underwent SOT, there was heterogeneity in the type of organ transplanted. This heterogeneity could translate to patient-level and institution-level differences in immunosuppression regimens, frequency of rejection, and time elapsed since SOT. Our multicenter study also allowed for differences between sites in FMT route of delivery, source of stool, and technical proficiency of endoscopists. Further studies will need to focus on efficacy, safety, and patient outcomes after FMT among specific CDI subgroups including patients who have severe CDI, fulminant CDI, and patients who do not respond to FMT-based therapy.
In conclusion, FMT in patients with a history of SOT appears to be a safe and effective treatment for CDI. There were no instances of bacteremia or CMV seroconversion due to FMT observed in our study cohort. However, a significant minority of CMV-seropositive patients had reactivation shortly after FMT, a finding that needs further elucidation and should be included in the informed consent process. Rates of cure after a single FMT are much lower for SOT patients with RCDI, severe CDI, and fulminant CDI, but can be improved to levels comparable to immunocompetent patients when additional therapies such as repeat FMT ± anti-CDI antibiotics are subsequently utilized. 
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